Pharma Business - March 4, 2014
AstraZeneca’s Delaware facilities sold
JPMorgan has bought half of AstraZeneca’s research campus in Delaware for $44 million. The 58-acre site forms the southern wing of AstraZeneca’s Wilmington-based American headquarters, and the drugmaker plans to vacate the site by year’s end, according to the Philadelphia Business Journal. The south campus was previously home to AstraZeneca’s Global Medicines Development unit. The […]
Drug Development Pharma - March 3, 2014
Green light for AstraZeneca’s Bydureon Pen
The FDA has approved the Bydureon Pen as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. The pen is a pre-filled, single-use pen injector, eliminating the need for the patient to transfer the medication between a vial and syringe during the self-injection process. It contains the same formulation and […]
Drug Development Pharma - February 25, 2014
FDA approves Myalept to treat rare metabolic disease
The U.S. Food and Drug Administration has approved AstraZeneca’s and Bristol-Myers Squibb’s Myalept as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. The safety and effectiveness of Myalept, an analog of leptin made through recombinant DNA technology, were evaluated in an open-label, […]
In a new job - February 13, 2014
Margareta Ozolins leads AZ Sweden Operations
AstraZeneca announces that Margareta Ozolins has been appointed new manager for Sweden Operations, the company’s production unit in Södertälje. Ozolins takes over after Per Alfredsson who is pursuing a position as manager for Global Supply Chain & Strategy. According to AstraZeneca Margareta Ozolins has a broad professional background and since starting at the company in […]
Drug Development Pharma - February 12, 2014
AstraZeneca’s Onglyza on review
The diabetes drug Onglyza is under the FDA’s microscope as the agency said it would review possible heart risks associated with the medication. The decision comes after a study published in the New England Journal of Medicine. The study flagged an increase in heart failure hospitalizations among patients who used Onglyza (saxagliptin). The active ingredient is […]
Drug Development Pharma - February 6, 2014
AstraZeneca cuts another 550 jobs
On February 6 AstraZeneca released its full quarter and full year results 2013 where it stood clear that the company expects another 550 layoffs due to savings. Of the 550 jobs, 168 of them will be cut off as the R&D unit in Avishkar (Bangalore, India) is closed down. The remaining 400 posts will be […]
